Loading...
Metabolic Capacity Expansion And Peptide Outsourcing Shifts Will Face Headwinds Yet Ultimately Support Upside
AN
AnalystLowTarget
Not Invested
Community Contributor
Published
16 Dec 25
Views
12
16 Dec
CHF 37.90
AnalystLowTarget's Fair Value
CHF 28.87
31.3% overvalued intrinsic discount1Y
77.5%7D
-1.0%1Y
77.5%7D
-1.0%You can edit this narrative until Dec 17 1:05 PM. Then, changes will post as Updates.
Author's Valuation
CHF 28.8731.3% overvalued intrinsic discount
AnalystLowTarget Fair Value